MILED Trial Informational Video 

Powering LAM Research Webinar 

 

The MILED Trial is a new research study designed to answer the question of whether we should be starting sirolimus at low doses earlier in the course of LAM, before symptoms develop and while lung function is still normal, similar to the manner in which we treat diabetes and high blood pressure early to prevent future heart and kidney complications.

You may be eligible if you:

  • Are an adult woman with LAM
  • Have an FEV1 greater than 70% predicted
  • Are not currently taking sirolimus

During the study, participants will:

  • Attend 8 study visits over 2 years (about one visit every 4 months)
  • Complete blood tests, a physical exam, and pulmonary function tests at visits
  • Answer questions about breathing, fatigue and quality of life
  • Take one capsule every day (1 mg sirolimus or a sugar pill) throughout the study
  • Record their pill taking and any side effects in an electronic diary

Participants will receive:

  • Physical exams, pulmonary function tests, a chest x-ray, and laboratory tests free of charge
  • Study drug (either 1 mg sirolimus or placebo) throughout the study
  • Reimbursement for travel expenses to attend each study visit


You can enroll in the MILED Trial and still participate in the LAM protocol at the NIH.

To get more information or to see if you may be eligible, please contact Susan McMahan, BSN, RN, CPN, CCRP, Project Manager at the University of Cincinnati, the clinical coordinating center for the study, or Frank McCormack, MD, Principal Investigator for MILED.We can answer your questions, provide additional information, and refer you to the closest MILED study site.  Susan’s contact information is: susan.mcmahan@uc.edu  phone: 513-558-4376.

Sites that are welcoming new participants are in Atlanta, Boston, Chicago, Cincinnati, Denver, Philadelphia, Seattle and Palo Alto. Coming soon: sites in New York City and Los Angeles!


Please see the LAM Foundation’s website or clinicaltrials.gov for more details about the MILED Trial.

 Please view the updated MILED Trial Travel Policy linked here.

 

 

MILED Trial Sites & Contact Information 

Site

Principal Investigator (PI)

Research Staff

CRC Contact Information

California

Los Angeles

UCLA

Ariss DerHovanessian, MD

Meilani Cayabyab

310-794-2926    mgcayabyab@mednet.ucla.edu

California

Palo Alto

Stanford University Medical Center

Stephen Ruoss, MD

Susan Jacobs

650-725-8083    ssjpulm@stanford.edu

Colorado

Denver

National Jewish Health

Gregory Downey, MD

Jami Henriksen

303-398-1233    henriksenj@njhealth.org

Georgia

Atlanta

Emory University

Srihari Veeraraghavan, MD

Tracy Halaby

404-714-7458    tracy.halaby@emory.edu

Illinois

Chicago

Loyola University

Dan Dilling, MD

Josie Corral

708-216-5744    jcorral@luc.edu

Massachusetts

Boston

Brigham and Women’s–Harvard

Elizabeth Henske, MD

Shefali Bagwe

857-307-0784    sbagwe@bwh.harvard.edu

New York

New York City

Columbia University

Jeanine D'Armiento, MD

Laura Fonseca

212-305-3745    lf2560@cumc.columbia.edu

Ohio

Cincinnati

University of Cincinnati

Frank McCormack, MD

Nishant Gupta, MD

Susan McMahan

513-558-4376    susan.mcmahan@uc.edu

Pennsylvania

Philadelphia

University of Pennsylvania

Maryl Kreider, MD

Sara Deitrick

215-615-0276    sara.deitrick@uphs.upenn.edu

Washington

Seattle

Swedish Minor and James

George Pappas, MD, MPH

Julie Wallick

206-215-3986    Julie.wallick@swedish.org